Approval · Notice of Compliance 29237 · 2022
IVOZFO: Notice of Compliance 29237
Issued October 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29237
- Date
- October 18, 2022
- Company
- Verity Pharmaceuticals IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To modify the indication by - removing: (i) osteomyelitis and (ii) nosocomial lower respiratory tract infection - adding: (i) bone and joint infections, (ii) hospitalacquired pneumonia, including ventilator-associated pneumonia, (iii) complicated intra-abdominal infections, (iv) complicated skin and soft tissue infections, and (v) infective endocarditis. To convert product monograph to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IVOZFO | Not yet assigned | — |
Medicinal ingredients
- FOSFOMYCIN SODIUM 2 G per VIAL
- FOSFOMYCIN SODIUM 4 G per VIAL
- FOSFOMYCIN SODIUM 8 G per VIAL